Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

TRVN opened at $1.28 on Thursday. The company has a fifty day moving average price of $1.62 and a two-hundred day moving average price of $2.14. The firm has a market capitalization of $1.11 million, a PE ratio of -0.03 and a beta of 1.05. Trevena has a 52 week low of $1.13 and a 52 week high of $12.25.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.